FTO and cancer: Targeting FTO with Dac51 rescued CD8+ T-cell function, and the combination of Dac51 and anti-PD-L1 blockade immunotherapy had a synergistic effect.241 These results highlight that targeting FTO is a potential cancer immunotherapy strategy.